Analysis of Efficacy and Safety of First Generation EGFR-TKI plus Apatinib in Treating Advanced NSCLC after EGFR-TKI Treatment Failure

被引：0
|
作者：
Feng, Y. [1 ]
Zhu, H. [1 ]
Hu, X. [1 ]
Liu, Y. [1 ]
Xing, P. [2 ]
Wang, H. [3 ]
Ji, X. [4 ]
Dai, Z. [4 ]
Shi, Y. [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med, Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Inst Hosp, Beijing, Peoples R China
[4] Huanxing Canc Hosp Chaoyang Dist, Shibalidian Township, Chaoyang Distri, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
EGFR-TKI; Apatinib; lung adenocarcinoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.50
引用
收藏
页码：S609 / S609
页数：1
相关论文
共 50 条
  • [1] Low Dose Apatinib Combined with EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure
    Chen, M.
    Song, J.
    Liu, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S873 - S873
  • [2] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
  • [3] The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
    Lu, S.
    Wang, Q.
    Zhang, G.
    Dong, X.
    Yang, C.
    Song, Y.
    Chang, G.
    Lu, Y.
    Pan, H.
    Chiu, C.
    Wang, Z.
    Feng, J.
    Zhou, J.
    Xu, X.
    Guo, R.
    Chen, J.
    Yang, H.
    Chen, Y.
    Yu, Z.
    Shiah, H.
    Wang, C.
    Yang, N.
    Fang, J.
    Wang, P.
    Wang, K.
    Hu, Y.
    He, J.
    Wang, Z.
    Shi, J.
    Chen, S.
    Cheng, Y.
    Su, W.
    Hsia, T.
    Cui, J.
    Sun, Y.
    Yang, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S208 - S209
  • [4] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S873 - S873
  • [5] Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [6] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [7] P2.14-27Efficacy and Prognostic Factor of Apatinib Plus EGFR-TKI in Treating Advanced Non-Small-Cell Lung Cancer with EGFR-TKI Resistance
    Dong, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S839 - S839
  • [8] Efficacy, Safety and Dosage of Afatinib in Patients with NSCLC after Failure of Prior EGFR-TKI
    Kim, Young-Chul
    Choi, Hayoung
    Park, Cheol-Kyu
    Oh, In-Jae
    Yun, Ju-Sik
    Song, Sang-Yun
    Na, Kook-Joo
    Ahn, Sung-Ja
    Yoon, Mee Sun
    Choi, Yoo-Duk
    Seon, Hyun-Ju
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S647 - S647
  • [9] Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism
    He, Y.
    Zhao, C.
    Li, X.
    Ren, S.
    Jiang, T.
    Zhang, J.
    Su, C.
    Chen, X.
    Cai, W.
    Gao, G.
    Li, W.
    Wu, F.
    Li, J.
    Zhao, J.
    Zhou, F.
    Hu, Q.
    Hirsch, F. R.
    Zhou, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1970 - S1970
  • [10] Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
    Takeda, Masayuki
    Okamoto, Isamu
    Tsurutani, Junji
    Oiso, Naoki
    Kawada, Akira
    Nakagawa, Kazuhiko
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (06) : 528 - 533
12345